Novavax Stock News

During May and June, Novavax (NASDAQ: NVAX ) shares appeared to be making a major comeback. At the time, news of a partnership deal with pharma firm Sanofi (NASDAQ: SNY ), as well as another positive

Nvidia (NASDAQ: NVDA ) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which spark

Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works.

Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ: NVAX ) the green light to targ

Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Glob

Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company

Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?

Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna.

Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?

Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.

Novavax stock remains under pressure despite winning a key designation for its malaria shot. Is NVAX stock a buy or a sell in January 2024?

Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.